Brent David A, Gibbons Robert D, Wilkinson Paul, Dubicka Bernadka
Western Psychiatric Institute and Clinic,University of Pittsburgh Medical Center.
The University of Chicago Biological Sciences.
BJPsych Bull. 2018 Feb;42(1):1-4. doi: 10.1192/bjb.2017.2.
In this paper, we summarise and critique a network meta-analysis (NMA) of antidepressant efficacy and tolerability for paediatric depression and an accompanying editorial. Although we agree that many of the extant studies are flawed, this meta-analysis showed clear efficacy of fluoxetine in the NMA, and for sertraline and escitalopram in pairwise analyses. Consequently, these papers underestimate the benefits of antidepressants for paediatric depression, and provide support for current practice guideline, which recommends the use of an antidepressant if the patient does not respond to psychotherapy. In these circumstances, fluoxetine should be the first choice, with escitalopram and sertraline as alternatives. Declaration of interest D.A.B. receives royalties from Guilford Press, has or will receive royalties from the electronic self-rated version of the C-SSRS from eResearch Technology, Inc., is on the editorial board of UpToDate, and is a reviewer for Healthwise. R.D.G. serves as an expert witness for the US Department of Justice, Pfizer, Wyeth and GSK; and is the founder of Adaptive Testing Technologies. P.W. receives personal fees from Lundbeck and Takeda. B.D. reports a licensing agreement with Lundbeck for a psychosocial treatment manual for depression. No other disclosures were reported.
在本文中,我们总结并评论了一项关于儿科抑郁症抗抑郁药疗效和耐受性的网络荟萃分析(NMA)以及一篇随附的社论。尽管我们认同许多现有研究存在缺陷,但该荟萃分析在NMA中显示出氟西汀的明确疗效,在成对分析中显示出舍曲林和艾司西酞普兰的明确疗效。因此,这些论文低估了抗抑郁药对儿科抑郁症的益处,并为当前的实践指南提供了支持,该指南建议如果患者对心理治疗无反应则使用抗抑郁药。在这些情况下,氟西汀应作为首选,艾司西酞普兰和舍曲林作为替代选择。利益声明:D.A.B.从吉尔福德出版社获得版税,已从或将会从eResearch Technology, Inc.的C-SSRS电子自评版本获得版税,是UpToDate的编辑委员会成员,并且是Healthwise的审稿人。R.D.G.担任美国司法部、辉瑞、惠氏和葛兰素史克的专家证人;并且是自适应测试技术公司的创始人。P.W.从灵北和武田获得个人报酬。B.D.报告与灵北就抑郁症心理社会治疗手册签订了许可协议。未报告其他披露情况。